The intractable complexity of AD pathology, encompassing multifaceted aberrations from Aβ aggregation and tau hyperphosphorylation to widespread neuroinflammation and synaptic dysfunction, urgently necessitates therapeutic strategies capable of simultaneously modulating multiple targets. This evidence concerns the gene MAPT and Alzheimer disease.